Featured News

The Search for Vaccine Targets For COVID-19

The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.

 

“With OU, we are acquiring the actual COVID-19 virus, and we will infect cells and look for the targets on the infected cells. We will use those targets to either develop a vaccine or to directly target them with something like monoclonal antibodies.”

 

Curtis McMurtrey, PhD,
Director of Immuno-Proteomics for Pure MHC and a graduate of the OU Health Sciences Center.

Other News

OKLAHOMA CITY, OK AND AUSTIN, TX – The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.

March 20, 2020

Emergent Technologies, Inc. (ETI) announced today that Steven Lloyd Mayer, MD has been hired as Chief Medical Officer to support commercialization efforts for its portfolio companies Pure MHC, LLC and Caisson Biotech, LLC . . .

February 13, 2019

Emergent Technologies, Inc. (ETI) announced today that its target discovery portfolio company, Pure MHC, and global biopharmaceutical company, AbbVie (NYSE:ABBV) will embark on a research and license agreement to discover and validate peptide targets for use with T-cell receptor therapeutics in several types of cancers.
January 09, 2017

Emergent Technologies, Inc. announced today that its portfolio company,
Receptor Logic, has entered into an exclusive License Agreement with Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for autoimmune diseases, asthma and
allergic diseases, and cancer.

January 12, 2016

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC)
announced an agreement with Pure MHC, an Emergent Technologies portfolio
company, for development of a novel assay for quality control that will be an
important component of ImmunoCellular’s ICT-107 phase 3 registrational
clinical program in newly diagnosed glioblastoma, anticipated to begin in the
second half of 2015.

June 22, 2015

A recent cancer study performed by the Washington University School of
Medicine in St. Louis has garnered significant interest from the science and
medical community. This research, led by Dr. Beatriz Carreno, tested the
ability of a personalized cancer vaccine to assist the immune system’s
effectiveness in attacking a patient’s specific tumor.

April 1, 2015

PhosImmune Inc. and PureMHC LLC today announced they have entered into a
license and collaboration agreement to develop novel antibody-based
immunotherapies designed to target cancers.

October 21, 2014